In a Diabetes Care perspective, 88% of at-risk people with low C-peptide got type 1 within five years, versus 41% with high levels. Authors report Sanofi ties.
Recap by typeshit. Full story at Managed Healthcare Executive.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
Compounds modeled on the weight loss blockbusters are also in trials for schizophrenia and Parkinson's disease, among other brain conditions.
A Medscape opinion roundup asks whether microdosing tirzepatide carries too much risk and whether surgery still matters, plus why sweet-and-salty snacks hook us.
Loading…